Anti-HER2 monoclonal antibody for ADC
Product | Unit size | Cat. code | Docs. | Qty. | Price | |
---|---|---|---|---|---|---|
Anti-HER2-hIgG1 HER2 antibody for conjugation assays - Human IgG1 |
Show product |
1 mg |
her2-mab1-1
|
|
Monoclonal human IgG1 antibody against HER2 for antibody-drug conjugation
InvivoGen provides Anti-HER2-hIgG1, a monoclonal antibody (mAb) specifically developed for the generation of antibody-drug conjugates (ADCs). This mAb features:
Anti-HER2 PRR ligand bioconjugation
(click to enlarge)
- the variable region of trastuzumab, which specifically targets the human epidermal growth factor 2 (HER2),
- a human IgG1 constant region that displays high effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC).
InvivoGen's Anti-HER2-hIgG1 has been generated by recombinant DNA technology, produced in CHO cells, and purified by affinity chromatography.
HER2 background
HER2 (human epidermal growth factor receptor 2), also known as HER2/neu or ERBB2, is a transmembrane protein expressed by epithelial cells that plays an important role in normal cell growth and differentiation [1]. HER2 overexpression causes uncontrollable cell proliferation, as most particularly evidenced in breast and ovarian cancers [1].
Therapeutic strategies aiming at killing HER2+ cancer cells use the FDA-approved trastuzumab, an anti-HER2-hIgG1 antibody. Binding of trastuzumab to HER2 results in cell death through different mechanisms, including antibody-dependent cell-mediated cytotoxicity and phagocytosis [2,3]. Antibody-drug conjugates (ADCs) combining trastuzumab with cytotoxic payloads allow targeted drug delivery to cancer cells in addition to the mAb-mediated effector functions [4].
Anti-HER2 ADC modes of action
(click to enlarge)
In a co-culture of HER2+ tumor cells and human peripheral blood monocytes (PBMCs), ADCs combining InvivoGen's Anti-HER2-hIgG1 and STING or TLR7 agonists induce a significantly higher production of IL-6 and CXCL10 pro-inflammatory cytokines than unconjugated agonists or negative control ADCs (see Figures).
Key features of Anti-HER2-hIgG1
- Clinically-relevant variable region targeting human HER2 (trastuzumab)
- Human IgG1 constant region for high effector functions
- Functionally validated by flow cytometry and ADC-based cellular assays
- The absence of bacterial contamination has been confirmed
InvivoGen offers conjugatable PRR ligands for building immunostimulatory Anti-HER2 ADCs.
You may choose from TLR7 and STING agonists:
- Conjugatable TLR7 agonists: TL7-887 and TL7-975
- Conjugatable STING agonists: STG-982 and STG-968
Learn more about bioconjugation
InvivoGen’s products are for research use only, and not for clinical or veterinary use.
References
1. Rubin I. & Yarden Y. 2001. The basic biology of HER2. Ann Oncol.12 Suppl 1:S3-8.
2. Collins DM. et al., 2012. Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann Oncol. 23(7):1788-95.
3. Petricevic B. et al., 2013. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. J Transl Med. 11:307.
4. Tarantino P. et al., 2022. Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 72:165-182.
Specifications
Specificity: Targets cells expressing HER2
Variable region biosimilar: Trastuzumab
Isotype: Human IgG1, Kappa
Source: Chinese hamster ovary (CHO) cells
Formulation: 0.2 μm filtered solution in 150 mM sodium chloride, 20 mM sodium phosphate buffer with 5% saccharose
Purification: Affinity chromatography with protein A
Tested Applications: Flow cytometry, Antibody-drug conjugation
Quality control:
- The binding of Anti-HER2-hIgG1 mAb to HER2 has been validated using flow cytometry and antibody-drug conjugate (ADC)-based cellular assays.
- The complete sequence of the antibody has been verified.
- The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ hTLR2 and HEK-Blue™ TLR4 cellular assays.
Contents
- 1 mg of purified Anti-HER2-hIgG1 monoclonal antibody (mAb), provided azide-free and lyophilized
The product is shipped at room temperature.
Store lyophilized antibody at -20 °C.
Lyophilized product is stable for at least 1 year. Reconstituted antibody is stable for 1 month at 4°C and for 1 year at -20°C. Avoid repeated freeze-thaw cycles.
Tags: buy Trastuzumab (anti-HER2) | Trastuzumab (anti-HER2) supplier | purchase Trastuzumab (anti-HER2) | Trastuzumab (anti-HER2) cost | Trastuzumab (anti-HER2) manufacturer | order Trastuzumab (anti-HER2) | Trastuzumab (anti-HER2) distributor
Back to the top